Shom Goel

机构：The University of Melbourne, Peter MacCallum Cancer Centre · ORCID：0000-0001-8329-9084

发表论文 231 篇 · 总被引 10546 次 · h-index 36

代表论文

• Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion (2024 · Cancer Cell · 被引 54)
• Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer (2025 · Journal for ImmunoTherapy of Cancer · 被引 19)
• Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion (2024 · Cancer Cell · 被引 17)
• Intracellular zinc protects tumours from T cell-mediated cytotoxicity (2024 · Cell Death and Differentiation · 被引 11)
• A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer (2025 · Clinical Cancer Research · 被引 10)
• 485MO Health-related quality of life (HRQoL) from the PATINA trial (AFT-38): Impact of adding palbociclib to HER2 and endocrine therapy (ET) after induction in HR+/HER2+ metastatic breast cancer (MBC) (2025 · Annals of Oncology · 被引 5)